Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576121 | PMC |
| http://dx.doi.org/10.1128/AAC.01165-15 | DOI Listing |
Publication Analysis
Top Keywords
klebsiella pneumoniae
8
pneumoniae isolate
8
report ceftazidime-avibactam
4
ceftazidime-avibactam resistance
4
resistance kpc-3-expressing
4
kpc-3-expressing klebsiella
4
isolate ceftazidime-avibactam
4
ceftazidime-avibactam antimicrobial
4
antimicrobial approved
4
approved fda
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!